Related Experiment Video
Updated: Apr 21, 2026

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
Published on: February 12, 2018
Central serous chorioretinopathy associated with the use of spironolactone, aldosterone receptor antagonist
Anna Gabrielian1, Mathew W MacCumber
1*Illinois Retina Associates, Harvey, Illinois †Department of Ophthalmology, Rush University Medical Center, Chicago, Illinois.
Purpose:
To report a case of central serous chorioretinopathy caused by the use of spironolactone, a competitive antagonist of aldosterone.
Methods:
Case report and review of the literature.
Results:
A 26-year-old white woman on Aldactone (spironolactone) for the treatment of acne and Adderall (dextroamphetamine/amphetamine) for the treatment of attention deficit hyperactivity disorder, developed central serous chorioretinopathy, which resolved upon discontinuation of spironolactone and remitted after restarting it.
Conclusion:
It is likely that spironolactone use contributed to the development of central serous chorioretinopathy in this patient. Concomitant use of amphetamine may also have played a role.
Related Concept Videos
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment
Glaucoma: Overview
Chronic Kidney Disease II: Clinical Manifestations
Diabetic Retinopathy
Nephrotic Syndrome II : Assessment and Medical Management

